LGP2
Ensembl | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| UniProt | |||||||||
| RefSeq (mRNA) | |||||||||
| RefSeq (protein) | |||||||||
| Location (UCSC) | Chr 17: 42.1 – 42.11 Mb | Chr 11: 100.59 – 100.6 Mb | |||||||
| PubMed search | [3] | [4] | |||||||
| View/Edit Human | View/Edit Mouse |
Probable ATP-dependent RNA helicase DHX58 also known as RIG-I-like receptor 3 (RLR-3) or RIG-I-like receptor LGP2 (RLR) is a
Structure and function
LGP2 was first identified and characterized in the context of
Since LGP2 lacks
LGP2 has been shown to directly interact[10] with RIG-I through its C-terminal repressor domain (RD). The primary contact sites in this interaction is likely between the RD of LGP2 and the CARD or helicase domain of RIG-I as it is seen with RIG-I self-association,[10] but this has not been confirmed. The helicase activity of LGP2 has been found to be essential for its positive regulation of RIG-I signaling.[9] Overexpression of LGP2 is able to inhibit RIG-I-mediated antiviral signaling both in the presence and absence of viral ligands.[10][11][12] This inhibition of RIG-I signaling is not dependent upon the ability of LGP2 to bind viral ligands and is therefore not due to ligand competition.[7][13] Although LGP2 binds to dsRNA with higher affinity,[12] it is dispensable for RIG-I-mediated recognition of synthetic dsRNA ligands.[9] RIG-I, when overexpressed[7] and in LGP2 knock-down studies,[14] has been shown to induce antiviral response in the absence of viral ligand.
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000108771 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000017830 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ PMID 11735219.
- ^ "Entrez Gene: LGP2 likely ortholog of mouse D11lgp2".
- ^ PMID 22301134.
- PMID 21175414.
- ^ PMID 20080593.
- ^ PMID 17190814.
- PMID 16210631.
- ^ PMID 16116171.
- PMID 20581823.
- S2CID 1899247.
Further reading
- Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. PMID 8125298.
- Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. PMID 8889548.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. PMID 9373149.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. PMID 12477932.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. PMID 14702039.
- Rual JF, Venkatesan K, Hao T, et al. (2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature. 437 (7062): 1173–8. S2CID 4427026.
- Komuro A, Horvath CM (2007). "RNA- and virus-independent inhibition of antiviral signaling by RNA helicase LGP2". J. Virol. 80 (24): 12332–42. PMID 17020950.
 | This article on a gene on human chromosome 17 is a stub. You can help Wikipedia by expanding it. |